CDKN2B and mesothelioma: Thank to this broad number of cases we could identify four subtypes of mesothelioma according to their molecular genetic alterations in CDKN2A, CDKN2B and BAP1. We also detected the occurrence of rare genomic alterations, which can be targeted with FDA-approved or experimental drugs.